Insider Cluster (2 insiders) ·Filed Aug 3, 2026

ALKS

Alkermes plc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago
Insider cluster: 2 insiders, $536K total
Actionable Insight • Neutral

The insider sales are too small to convey a material signal. Monitor for larger insider transactions or changes in guidance that could indicate management's view on the business trajectory.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
ALKS ▼ -4.97% at T+20d
NEUTRAL call ✗ call lost -4.97% · α vs SPY -3.73% · entry $49.67 → $47.20
Next anchor: T+60d in 25d
Latest observation: T+39 -39.24% FF3 residual α
Entry anchored
Aug 3, 06:28 PM ET
via exchange tick
T+1d
-0.12%
call -0.12% · α +0.08%
$49.61
settled 8w ago
T+5d
-0.93%
call -0.93% · α -0.83%
$49.21
settled 8w ago
T+20d
-4.97%
call -4.97% · α -3.73%
$47.20
settled 5w ago
T+60d
—
call — · α —
—
in 25d

Price Chart

Loading chart...

Executive Summary

Two Alkermes executives (EVP CLO and EVP R&D/CMO) sold a combined $536K in open-market shares on August 3, 2026, one week after the company reported a Q2 EPS miss and widened GAAP net loss guidance. The sales are trivial relative to the $8.2B market cap (0.0065%) and likely represent routine post-earnings transactions rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$536.0K
Insiders
2

Key Facts

  • EVP CLO David Gaffin sold 2,034 shares at $48.58 for ~$99K
  • EVP R&D/CMO Craig Hopkinson sold 9,000 shares at $48.58 for ~$437K
  • Total open-market sales of $536K represent 0.0065% of Alkermes' $8.2B market cap
  • Sales occurred 7 days after Q2 2026 earnings miss (EPS $0.00 vs $0.29 consensus) and widened GAAP net loss guidance

Financial Impact

Total open-market sales of $536K represent 0.0065% of $8.2B market cap, immaterial.

insider selling

Risk Factors

  • Insider sales could accelerate if Q3 results disappoint further
  • GAAP net loss guidance widening may pressure the stock if not offset by LUMRYZ revenue growth

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ALKS-1785801678578
18 reports for ALKS
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +25.88%May 12, 2026
Filters
Rows
Reports for ALKS — sortable, filterable
TypeNow
Sep 16, 2026
16d ago
8-K
NEUTRAL ★ 2/10
$46.07 $42.13▼ −8.55%▼ −11.12%$41.64 (−9.62%)
Sep 3, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$46.10 $45.83▼ −0.59%▲ +0.62%$41.64 (−9.67%)
Aug 3, 2026
8w ago
Insider Cluster
BEARISH ★ 4/10
$49.67 $49.21▲ +0.93%▲ +0.83%$41.64 (+16.17%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.64 (−16.17%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.64 (−16.17%)
Jul 28, 2026
9w ago
8-K
BEARISH ★ 6/10
$50.50 $49.53▲ +1.92%▲ +4.19%$41.64 (+17.54%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$54.29 $51.60▼ −4.95%▼ −5.82%$41.64 (−23.30%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.14 $51.94▼ −5.80%▼ −6.29%$41.64 (−24.48%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$42.80 $44.28▲ +3.46%▲ +2.89%$41.64 (−2.71%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$41.19 $44.29▲ +7.53%▲ +10.50%$41.64 (+1.10%)
Showing 10 of 18

US Market Status

Market Open — Closes in 2h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 4, 2026